AMLX News and Press, Amylyx Pharmaceuticals Inc. From 02/23/24

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has granted stock options and restricted stock units (“RSUs”) to Linda Arsenault, the Company’s newly appointed Chief Human Resources Officer. The Com...

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now . Class Period: Nov. 11, 2022 – Nov. 8, 2023 Lead Plaintiff Deadline: Apr. 9, 2024 ...

2024-02-21 11:02:17 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector Amylyx Pharmaceuticals: Balancing Growth And Market Challenges (Rating Downgrade) Amylyx Pharma falls as chief commercial officer departs Seek...

Philadelphia, Pennsylvania--(Newsfile Corp. - February 16, 2024) - Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a commercial-stage biotechnology company that engages in the discovery and development of treatments for ALS, also known as Lou Gehrig's disease, and other neurodegenerative diseases....

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide (ASO), AMX0114, for the potential treatment of amyotro...

Do you, or did you, own securities of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)? Did you purchase your securities between November 11, 2022 and November 8, 2023, inclusive? Did you lose money in your investment in Amylyx Pharmaceuticals, Inc.? Do you want to discuss your rights? ...

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Amylyx Pharm...

AMLX Investors with Substantial Losses Encouraged to Contact Hagens Berman, National Trial Attorneys San Francisco, California--(Newsfile Corp. - February 14, 2024) - Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losse...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 ...